WR 279,396

PreclinicalSmall molecule

UU.S. Army Medical Research and Development Command

WR 279,396 is one of 9 small molecule programs targeting Leishmaniasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeishmaniasisActive, not recruiting

LeishmaniasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Leishmaniasis

#DrugCompanyPhaseTrials

Pentam

FFresenius Kabi USA, LLC

Approved

—2

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Approved

—3

Abelcet

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Garamycin

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—6

Vfend

PPrism Pharmaceuticals

Approved

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—8

Impavido

KKnight Therapeutics (USA) Inc

Phase 3

7 9

WR 279,396

UU.S. Army Medical Research and Development Command

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cutaneous Leishmaniasis8 trials

WR 279,396 for the Treatment of Cutaneous Leishmaniasis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01988909·18 enrolled

Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT00703924·92 enrolled

A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT01536795·48 enrolled

Show 5 more trials

Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)

Completed·UU.S. Army Medical Research and Development Command·Phase 3·NCT00606580·375 enrolled

Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT01083576·30 enrolled

Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT01032382·30 enrolled

Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis

Terminated·UU.S. Army Medical Research and Development Command·Phase 2·NCT01140191·1 enrolled

Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

Completed·UU.S. Army Medical Research and Development Command·Phase 3·NCT01790659·399 enrolled

Leishmaniasis1 trial

Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application

Completed·UU.S. Army Medical Research and Development Command·N/A·NCT00490230·108 enrolled

Treatment1 trial

WR 279,396 Open Label Treatment Protocol in Tunisia

Terminated·UU.S. Army Medical Research and Development Command·Phase 2·NCT01494350·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for WR 279,396. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WR 279,396 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WR 279,396. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — U.S. Army Medical Research and Development Command company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UU.S. Army Medical Research and Development Command

WR 279,396

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cutaneous Leishmaniasis8 trials

Leishmaniasis1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News